Skip to content

California Cannabis Industry Association Partners

Legislative Team

PrecisionAdvocacy_RGB_PrimaryLogo_Black
unnamed(1)
TLA

Precision Advocacy

State Lobbyist

Gavin Newsom
Governor, California


Newsom is widely recognized for his willingness to lead – repeatedly developing, advocating, and implementing innovative and groundbreaking solutions to some of our most challenging issues. On a wide range of topics including same-sex marriage, gun safety, marijuana, the death penalty, universal health care, access to preschool, technology, criminal justice reform, and the minimum wage, Newsom stuck his neck out and did the right thing, which often led to sweeping changes when his policies were ultimately accepted, embraced, and replicated across the state and nation.

Newsom’s top priorities for his administration are tackling our state’s affordability crisis, creating inclusive economic growth and opportunity for every child, and standing up for California values — from civil rights, to immigration, environmental protection, access to quality schools at all levels, and justice.

Governor Newsom is married to Jennifer Siebel Newsom. They have four children: Montana, Hunter, Brooklynn, and Dutch.

The Liaison Group

Federal Lobbyist

Eleni Koualaski
Lieutenant Governor, California

Eleni Kounalakis is a California businesswoman, a wife and the mother of two teenage sons, and the former U.S. Ambassador to Hungary under President Barack Obama. Eleni was raised the proud daughter of an immigrant father who started out as a farmworker, and she believes in the values of hard work, education and political activism.

In 1992, Eleni started her career as a staff member of the California Democratic Party in Sacramento and worked in the historic election, which elected two women to the U.S. Senate and turned California blue.

After the election, Eleni joined her family business, AKT Development, one of California’s most respected housing development firms. Over the next 18 years, Eleni worked her way up from project manager to president. Her work delivering housing for middle-class families in the Sacramento region earned her recognition as one of Sacramento’s most prominent businesswomen.

In 2010, Eleni was appointed by President Barack Obama as the U.S. Ambassador to Hungary and served side-by-side President Obama and Secretary Hillary Clinton promoting democracy. She is the author of the highly acclaimed book, Madam Ambassador, Three Years of Diplomacy, Dinner Parties and Democracy in Budapest, published in 2015 by The New Press.

During her 18 years in the housing industry, Ambassador Kounalakis continued to work as a democratic activist, working on the campaigns of countless progressive candidates and initiatives. Passionate about early childhood development, she served on California’s First 5 Commission and the California Blue Ribbon Commission on Autism. She was appointed by Mayor Ed Lee to the San Francisco Port Commission, and currently chairs the California Advisory Council for International Trade and Investment.

Eleni Kounalakis graduated from Dartmouth College in 1989, and earned her MBA from UC Berkeley’s Haas School of Business in 1992. She also holds an Honorary Doctorate of Laws from the American College of Greece. She lives in San Francisco with her husband, veteran journalist Markos Kounalakis, and their two sons Neo and Eon.

Non Profit Partners

CalAsian

CalAsian Chamber of Commerce

In 2010 the CalAsian Chamber was founded to give a voice to the over 600,000 Asian Pacific Islander (API) owned businesses in California. Today, the CalAsian Chamber is the largest statewide ethnic chamber in California, with the mission to grow and empower the API business community throughout California.

CalAsian Chamber advocates for policies, legislation and programs that will help California’s API-owned businesses community reach new markets and provide growth opportunities.

CalAsian Chamber works consistently on creating sustainable communities through economic development and focuses on providing access, education and opportunities for California’s API and small business community.

FullSizeRender-1

SEOWA

Social Equity Owners & Workers Association (“SEOWA"“) is a collective of Social Equity Applicants advocating for the advancement of social equity.

Our mission is a commitment to fairness, justice, and equality in the formulation of public policy, distribution of education services, implementation of community reinvestment, and oversight of institutions serving disadvantaged communities.

 

SEOWA

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.
Resource-Innovation-Institute_logo

Resource Innovation Institute

The mission of Resource Innovation Institute is to advance resource efficiency to cultivate a better agricultural future. We achieve our mission by focusing our work in three areas: Baselines & Benchmarks, Policies & Programs, Standards & Best Practices.

RII is a passionate team of multi-disciplinary leaders addressing the opportunity to rapidly transform resource-intensive agricultural sectors toward hyper-efficient production models.

supernova_default.66021acbfd4ca39b6a5e5286c2bf5077

Supernova Women

A Space for Women of Color in Cannabis

Supernova Women is a women of color led non-profit organization with a mission to empower people of color to become self-sufficient shareholders in the cannabis industry. We do this through education, advocacy, and network building.

Our organization was founded in 2015 by Amber Senter, Nina Parks, and Tsion “Sunshine” Lencho. Andrea Unsworth joined the Supernova Women board of directors in early 2016. Supernova Women is a national organization headquartered in Oakland, California

index

California NORML

Founded in 1972, California NORML is a non-profit, membership organization dedicated to reforming California’s marijuana laws. We are the only state organization advocating for sensible and fair cannabis laws and regulations on behalf of consumers. We lobby lawmakers, promote events, publish newsletters, offer legal and consumer health advice, and sponsor scientific research.

hood incubator

The Hood Incubator

BUILDING A MOVEMENT: We are growing a national network of on-the-ground cannabis leaders around the nation who are building and winning local cannabis campaigns in their communities.

ECONOMIC DEVELOPMENT: We empower Black community members to thrive as workers, owners and investors in the growing legal cannabis economy.

COMMUNITY EDUCATION: We mobilize the Black cannabis community and allies to identify opportunities of interests within communities most harmed by the war on drugs.

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

Association Partners

INCBA_Horiz_Logo_RGB-2
CMA-Logo-Horizontal-01
International_Cannabis_Farmers_Association_-_Gold

INCBA

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

CMA

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

ICFA

Lindsay Robinson
Executive Director, CCIA

Prior to becoming the Executive Director of the California Cannabis Industry Association, Lindsay was the Director of Development for the Marijuana Policy Project (MPP). Lindsay oversaw MPP’s national fundraising and membership strategies. Based in San Francisco, Lindsay was a key member of MPP’s fundraising team starting in 2010 and took the helm of the department in early 2014. MPP was responsible for passing adult use ballot initiatives in Nevada, Massachusetts, and Maine in 2016 while playing a supporting role in California with Prop 64. Lindsay’s team at MPP helped raise over $18 million for these campaigns in the 2016 election cycle.

She was one of the primary fundraisers for both Amendment 64, the 2012 ballot initiative to regulate cannabis like alcohol in Colorado, and Ballot Measure 2, a similar initiative that made cannabis legal in Alaska in 2014. Lindsay was elected to the Board of Directors for the California Cannabis Industry Association in January 2016 and served as the Chair of the Legislative Committee that same year.

Lindsay has been working to end cannabis prohibition for two decades, in both volunteer and professional capacities. Her passion for social justice has also led to more than 17 years in the nonprofit industry, fundraising for organizations like the SF-Marin Food Bank, the Center for Justice and Accountability, and La Raza Centro Legal. Lindsay received her undergraduate degree in Environmental Studies at the University of Vermont and has her Master’s in Nonprofit Administration from the University of San Francisco. She’s also a registered yoga instructor and tequila enthusiast, not necessarily in that order.
cda
CCMA_logo-600x198
LCCS

CDA

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

CCMA

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

CCMA

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

Industry Partners

unnamed 65
Headset
CannabizMedia-300x300
57684665064028aa36ddce8c_CLS Logo.300

Indiva Advisors

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

Headset Analytics

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

Cannabiz Media

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

Capitol Live Scan

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.
Cannabis-Trainers-logo-png-smaller
unnamed 65
unnamed(1)
unnamed(1)

Cannabis Trainers

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

dispensaries.com

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

Member-to-Member Services

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.

CCIA Membership Directory

Dr. Swetha Kaul
CCIA Board Vice President

Dr. Swetha Kaul is an industry expert on cannabis laboratory testing and a passionate advocate for sensible regulations. She has over a decade of leadership and technical experience from academia, the pharmaceutical industry and the emerging field of cannabis testing. She has an MS in Pharmacology and Toxicology and a PhD in Analytical Chemistry from University of Kansas. Prior to joining the cannabis industry, Dr. Kaul worked at Allergan where she was responsible for leading drug development efforts including formulation research, stability studies, process development and CMC.

Her foray into cannabis began when she took on the role of Chief Scientific Officer at Cannalysis, a cannabis testing lab based in Santa Ana, California. At Cannalysis, she pioneered industry leading analytical techniques and standards for quality and compliance while guiding the lab through several successful audits and accreditations. Her ability to simplify scientific and regulatory concepts to a variety of audiences has made her an established presence at major events such as SXSW, MJBizCon, CCBC, CWCBExpo, Arcview, CCIA’s Policy Summit, Analytical Cannabis, Emerald Conference and Infused Products Conference. Dr. Kaul is recognized as a scientific authority in the cannabis community and has been featured by various media outlets such as NPR, CBS, and Spectrum News. As a member of the CCIA Board of Directors and Chair of the Quality Control Committee, Dr. Kaul has participated in developing and promoting key legislative and regulatory policies. She is committed to legitimizing the cannabis industry through education and advocacy.
Scroll To Top